Get started
Akero Therapeutics, Inc.Akero Therapeutics, Inc.Akero Therapeutics, Inc.

Akero Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

AKRO chart


Full chart

AKRO upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪2.14 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−3.75 USD
Net income (FY)
‪−151.76 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪58.43 M‬
Beta (1Y)
1.38

Employees


Employees (FY)
56
Change (1Y)
+18 +47.37%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−2.71 M‬ USD

About Akero Therapeutics, Inc.


Sector
Health Technology
CEO
Andrew Cheng
Headquarters
South San Francisco
Website
akerotx.com
Founded
2017
FIGI
BBG00L9211Y8
Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph in January 2017 and is headquartered in South San Francisco, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

AKRO news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of AKRO is 30.64 USD — it has decreased by −1.27% in the past 24 hours. Watch Akero Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Akero Therapeutics, Inc. stocks are traded under the ticker AKRO.
AKRO stock has fallen by −5.97% compared to the previous week, the month change is a −1.02% fall, over the last year Akero Therapeutics, Inc. has showed a 85.11% increase.
We've gathered analysts' opinions on Akero Therapeutics, Inc. future price: according to them, AKRO price has a max estimate of 65.00 USD and a min estimate of 35.00 USD. Watch AKRO chart and read a more detailed Akero Therapeutics, Inc. stock forecast: see what analysts think of Akero Therapeutics, Inc. and suggest that you do with its stocks.
AKRO reached its all-time high on Jun 13, 2023 with the price of 58.38 USD, and its all-time low was 7.52 USD and was reached on Jun 13, 2022. View more price dynamics on AKRO chart.
See other stocks reaching their highest and lowest prices.
AKRO stock is 5.77% volatile and has beta coefficient of 1.38. Track Akero Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Akero Therapeutics, Inc. there?
Today Akero Therapeutics, Inc. has the market capitalization of ‪2.17 B‬, it has increased by 0.19% over the last week.
Yes, you can track Akero Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Akero Therapeutics, Inc. is going to release the next earnings report on Mar 13, 2025. Keep track of upcoming events with our Earnings Calendar.
AKRO earnings for the last quarter are −1.05 USD per share, whereas the estimation was −0.88 USD resulting in a −19.50% surprise. The estimated earnings for the next quarter are −1.16 USD per share. See more details about Akero Therapeutics, Inc. earnings.
Akero Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
AKRO net income for the last quarter is ‪−72.70 M‬ USD, while the quarter before that showed ‪−55.99 M‬ USD of net income which accounts for −29.86% change. Track more Akero Therapeutics, Inc. financial stats to get the full picture.
No, AKRO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has 56.00 employees. See our rating of the largest employees — is Akero Therapeutics, Inc. on this list?
Like other stocks, AKRO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Akero Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Akero Therapeutics, Inc. technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Akero Therapeutics, Inc. stock shows the buy signal. See more of Akero Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.